INTRUSION INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INTRUSION INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.02M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.77M | Mar 25, 2026 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $6.10M | Mar 29, 2017 |
| FY2016 | Dec 31, 2015 | $6.82M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $7.22M | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | $7.66M | Mar 27, 2015 |
| FY2013 | Dec 31, 2012 | $6.70M | Mar 28, 2014 |
| FY2012 | Dec 31, 2011 | $5.35M | Mar 28, 2013 |
| FY2011 | Dec 31, 2010 | $5.59M | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.38M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.43M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $4.35M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $4.18M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.66M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.91M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $8.30M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $6.43M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $4.04M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $3.92M | Mar 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.06M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($7.79M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($13.89M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($16.23M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($18.80M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.52M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $4.47M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.29M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($30.0K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.55M) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.16M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($8.45M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($12.05M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($16.28M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.50M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.52M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $4.51M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.48M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($749.0K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.41M) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.17M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.44M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $5.56M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $6.33M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.80M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.31M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.24M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.16M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $2.50M | Mar 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.76M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($6.29M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($7.77M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($13.19M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.56M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.18M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $4.29M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.58M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $272.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($1.24M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $777.0K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $533.0K | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $157.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $307.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.06M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $320.0K | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $260.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $202.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $20.0K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $47.0K | Mar 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.39M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $11.51M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $6.25M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.28M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.23M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.88M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $6.84M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $4.07M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $1.45M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.28M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.28M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $6.25M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($9.56M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | ($4.22M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $15.66M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $3.56M | Mar 18, 2022 |
| FY2019 | Dec 31, 2018 | ($1.06M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($3.51M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($3.40M) | Mar 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($127.07M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($118.01M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($110.22M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($96.33M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($80.10M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($61.30M) | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | ($54.78M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($59.24M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($61.53M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($61.50M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.62M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.85M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $139.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $3.02M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $4.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $16.70M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | $3.33M | Mar 9, 2021 |
| FY2020 | Dec 31, 2018 | $1.65M | Mar 9, 2021 |
| FY2019 | Dec 31, 2017 | $224.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $64.0K | Mar 28, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (11) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (16) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (11) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (16) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.12M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 15.59M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 1.85M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 1.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 19.13M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 17.42M | Mar 18, 2022 |
| FY2020 | Dec 31, 2019 | 13.54M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 13.25M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 12.80M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 12.75M | Mar 29, 2018 |